Inhibit Immune Response In Implantable Medical Devices

Description:

Anti-Inflammatory Protein Immobilization to Combat In-Stent Restenosis

 

Market Need

 

Over 200 million people worldwide suffer from occlusive vascular disease (OVD), with prevalence rates increasing sharply given the aging global population. The definitive first line therapy for OVD is stent-angioplasty, however, restenosis, caused by the immune system’s inflammatory response, poses a serious problem for effective treatment. The emergence of drug-eluting stents (DES) significantly reduced the risk of restenosis, however, DES inhibit the regrowth of endothelial tissue and increase the incidence of late stent thrombosis.

 

Technology Overview

 

Dr. Robert Levy and his team developed an approach to bind transmembrane protein CD47 onto the stent surface. When bound to signal regulator protein alpha (SIRPα) on the immune cell surface, CD47 acts as a marker of self, inhibiting inflammatory cell attachment, phagocytosis and cytokine release. CD47 modified stent surfaces implanted in rats showed a significant reduction in thrombi formation, and incidence of restenosis by 30%.

 

Advantages

•       Concept proven in vivo with polymeric and metallic surfaces

•       Addresses clot-formation prevalent with drug-eluting stents (DES) use

Application

•       This technology can be used with any implantable polyurethane containing device susceptible to degradation due to reactive oxygen species

Stage of Development: In vivo proof of concept

Case ID:
0429-09-Stachelek
Web Published:
5/9/2017
Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Simone Temporal
Licensing Associate
The Children's Hospital of Philadelphia
temporals@email.chop.edu
Inventors:
Stanley Stachelek
Dennis Discher
Robert Levy
Masako Ueda
Richard Tsai
Keywords:
CD47